Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. more
Time Frame | IPSC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -16% | -3.35% | -2.97% |
1-Month Return | -17.97% | -3.49% | -0.66% |
3-Month Return | -38.24% | -12.6% | 2.71% |
6-Month Return | -60.97% | -6.91% | 7.21% |
1-Year Return | -56.25% | 1.19% | 23.04% |
3-Year Return | -93.46% | -0.21% | 28.43% |
5-Year Return | -95.4% | 33.09% | 82.88% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | 1.06M | 5.20M | 2.23M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":20.35,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":42.99,"profit":true}] |
Cost of Revenue | 249.00K | 1.75M | 4.58M | 10.07M | 13.04M | [{"date":"2019-12-31","value":1.91,"profit":true},{"date":"2020-12-31","value":13.45,"profit":true},{"date":"2021-12-31","value":35.13,"profit":true},{"date":"2022-12-31","value":77.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (249.00K) | (1.75M) | (4.58M) | (4.87M) | (10.81M) | [{"date":"2019-12-31","value":-24900000,"profit":false},{"date":"2020-12-31","value":-175400000,"profit":false},{"date":"2021-12-31","value":-458200000,"profit":false},{"date":"2022-12-31","value":-487200000,"profit":false},{"date":"2023-12-31","value":-1080900000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (433.08%) | (93.71%) | (483.62%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":-433.08,"profit":false},{"date":"2022-12-31","value":-93.71,"profit":false},{"date":"2023-12-31","value":-483.62,"profit":false}] |
Operating Expenses | 20.03M | 49.18M | 94.88M | 139.03M | 148.78M | [{"date":"2019-12-31","value":13.46,"profit":true},{"date":"2020-12-31","value":33.05,"profit":true},{"date":"2021-12-31","value":63.77,"profit":true},{"date":"2022-12-31","value":93.45,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (245.98M) | (53.90M) | (94.88M) | (133.83M) | (146.55M) | [{"date":"2019-12-31","value":-24597900000,"profit":false},{"date":"2020-12-31","value":-5389800000,"profit":false},{"date":"2021-12-31","value":-9488300000,"profit":false},{"date":"2022-12-31","value":-13383100000,"profit":false},{"date":"2023-12-31","value":-14654600000,"profit":false}] |
Total Non-Operating Income/Expense | 1.75M | (58.00K) | (2.17M) | 1.59M | 17.62M | [{"date":"2019-12-31","value":9.9,"profit":true},{"date":"2020-12-31","value":-0.33,"profit":false},{"date":"2021-12-31","value":-12.33,"profit":false},{"date":"2022-12-31","value":9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (244.77M) | (53.58M) | (95.78M) | (130.84M) | (134.79M) | [{"date":"2019-12-31","value":-24476900000,"profit":false},{"date":"2020-12-31","value":-5357500000,"profit":false},{"date":"2021-12-31","value":-9578100000,"profit":false},{"date":"2022-12-31","value":-13084100000,"profit":false},{"date":"2023-12-31","value":-13479200000,"profit":false}] |
Income Taxes | 1.21M | 1.08M | 43.00K | 91.00K | 1.88M | [{"date":"2019-12-31","value":64.33,"profit":true},{"date":"2020-12-31","value":57.68,"profit":true},{"date":"2021-12-31","value":2.29,"profit":true},{"date":"2022-12-31","value":4.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (245.98M) | (54.66M) | (95.82M) | (130.93M) | (136.67M) | [{"date":"2019-12-31","value":-24597900000,"profit":false},{"date":"2020-12-31","value":-5466000000,"profit":false},{"date":"2021-12-31","value":-9582400000,"profit":false},{"date":"2022-12-31","value":-13093200000,"profit":false},{"date":"2023-12-31","value":-13667300000,"profit":false}] |
Income From Continuous Operations | (244.77M) | (53.58M) | (95.82M) | (130.93M) | (128.96M) | [{"date":"2019-12-31","value":-24476900000,"profit":false},{"date":"2020-12-31","value":-5357500000,"profit":false},{"date":"2021-12-31","value":-9582400000,"profit":false},{"date":"2022-12-31","value":-13093200000,"profit":false},{"date":"2023-12-31","value":-12895700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (245.98M) | (54.66M) | (95.82M) | (130.93M) | (136.67M) | [{"date":"2019-12-31","value":-24597900000,"profit":false},{"date":"2020-12-31","value":-5466000000,"profit":false},{"date":"2021-12-31","value":-9582400000,"profit":false},{"date":"2022-12-31","value":-13093200000,"profit":false},{"date":"2023-12-31","value":-13667300000,"profit":false}] |
EPS (Diluted) | (0.51) | (0.95) | (5.04) | (4.00) | (2.29) | [{"date":"2019-12-31","value":-51.38,"profit":false},{"date":"2020-12-31","value":-95.17,"profit":false},{"date":"2021-12-31","value":-504,"profit":false},{"date":"2022-12-31","value":-400,"profit":false},{"date":"2023-12-31","value":-229,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IPSC | |
---|---|
Cash Ratio | 10.00 |
Current Ratio | 10.39 |
Quick Ratio | 10.46 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IPSC | |
---|---|
ROA (LTM) | -20.90% |
ROE (LTM) | -62.61% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IPSC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.50 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.50 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IPSC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 33.26 |
P/B | 0.45 |
Price/FCF | NM |
EV/R | 1.96 |
EV/Ebitda | 0.08 |
Century Therapeutics Inc (IPSC) share price today is $1.05
Yes, Indians can buy shares of Century Therapeutics Inc (IPSC) on Vested. To buy Century Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IPSC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Century Therapeutics Inc (IPSC) via the Vested app. You can start investing in Century Therapeutics Inc (IPSC) with a minimum investment of $1.
You can invest in shares of Century Therapeutics Inc (IPSC) via Vested in three simple steps:
The 52-week high price of Century Therapeutics Inc (IPSC) is $5.51. The 52-week low price of Century Therapeutics Inc (IPSC) is $0.98.
The price-to-earnings (P/E) ratio of Century Therapeutics Inc (IPSC) is
The price-to-book (P/B) ratio of Century Therapeutics Inc (IPSC) is 0.45
The dividend yield of Century Therapeutics Inc (IPSC) is 0.00%
The market capitalization of Century Therapeutics Inc (IPSC) is $88.86M
The stock symbol (or ticker) of Century Therapeutics Inc is IPSC